NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech’s autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing.

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech's autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing.

What if we could combine our autofluorescent viruses with state of the art nebulization chambers to investigate airborne disinfection? What if we had the ability to measure and visualize if a room has been correctly decontaminated ? What if we could measure viral persistence following airborne dispersion. Well, we can. We are very proud to announce our strategical alliance with VirexpR, the leader in airborne disinfection testing in France. This collaboration will allow NeoVirTech to use VirexpR nebulization room (2,5 and 20m3) to disperse its autofluorescent virus and to measure the efficiency of air treatment devices using an imaged based readout. The alliance provides customer with a unique way to measure and visualize directly airborne disinfection efficiency and efficacy of respiratory protection for example. Contact us to know more : contact@neovirtech.com, contact@virexpr.fr

Picture is presenting VirexpR 2.5 m3 chamber in which NeoVirTech VACV ANCHOR poxvirus was nebulized, recovered using Coriolis aspiration and then confocal microscopy imaged following human cell infection to calculate the number of infectious and replicating particles (green infected cell, blue dot viral DNA, magenta cell marker).

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market

NeoVirTech (NVT) and BioImmunitas Ltd enter a long-term partnership to advance a human recombinant protein therapeutic platform from bench to bedside. BioImmunitas Ltd has developed a highly cost-efficient series of recombinant proteins which form the platform therapeutic agent. This highly innovative treatment has been shown to be efficacious in several different therapeutic areas. Their collaboration with NeoVirTech has seen BioImmunitas utilize NVT’s proprietary antiviral discovery platform to position its own therapeutic hRPP on the anti-viral market.